PB0294: Binational experience on aids treatment with a low molecular weight natural carbohydrate (eca 10-142), as stimulator over the immune system

Cevallos Arellano Edwin, Chief of the Oncology Clinic of the Metropolitan Hospital, Quito, Ecuador; Ardilla Ardilla, Henry, Director of the Colombian League to Fight Against AIDS, Santafe de Bogotá, D.C. , Colombia.

OBJECTIVES:
Evaluate stimulating properties of the low molecular weight (ECA 10-142) natural carbohydrate over the immume system in 70 patients suffering AIDS, IV CDC stage.

METHODS:
Seventy patients with confirmed AIDS diagnosis were selected: 30 colombian nationality and 40 ecuadorian nationality, to be orally treated with (ECA 10-142), for a 9 months period. For evaluation purposes, the symptoms and clinical signs, as well as total percentage of lymphocytes, percentage of cells CD4 and CD8 and its relation were considered.

In vitro studies demonstrated also that this carbohydrate stimulates the immune system of patients with AIDS.

RESULTS:
The results obtained through nine months, demonstrated a signs and symptoms clinical improvement in 64 patients (91. 4%); immunological recovery of CD4 levels in 66 patients (91. 3%); a clinical and immunological improvement was noticed in 64 patients (91. 4%); due to the advanced status of the illness, 4 patients (5. 7%) died. They received treatment for one month only and their CD4 levels were under 100.

DISCUSSION AND CONCLUSION:
(ECA 10-142) has proved to be a useful stimulus both, in vitro and in vivo over the immune system, because it inhibits the MASAS SINCITIALES formation in 59% and it is effective on the clinical and immunological improvement of patients with AIDS.

It is required that kinetic studies and researches to the long term be carried out to determine its immune-stimulating activity in patients with AIDS.

PB0294 BIRM® ECA 10-142, the low molecular weight carbohydrate, controls AIDS. Cevallos A. Edwin, Dr. , Chief of the Oncology and Radiotherapy Services, Metropolitan Hospital, Quito, Ecuador

OBJECTIVE:
In vitro studies carried out with BMR ECA 10-142, report the absence of cytotoxic effects, even at the highest concentration tested, and a moderate anti-HIV activity with a 59% reduction of the SINCITIA formation (Southern Research Institute, Birmingham, Alabama, U.S.A. , July 1991).

Double blind in vivo tests reported an increased number of CD4 cells.

The chemical analysis report on Nuclear Magnetic Resonance stated the empiric formula C3H502, or a multiple of it.

METHODS:
Twenty patients at CDC IV stage were selected, and they survived from January 1989 to April 1993.

CD4 cells were obviously increased in every patient. For instance, from 145 CD4 cells to 480 CD4 cells, within 3 months of treatment with BIRM®.

RESULTS:
Results were evaluated based on the number of CD4, CD8 and CD4/CD8 quotient, and the clinical evolution of the patient in regards to his signs and symp